TMDXTransMedics Group, Inc.
Price
-36%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, price roughly fair, growing in the filings, the market undecided.
We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
TransMedics Group, Inc. (TMDX) reported revenue of $190M in Q2 2026 (quarter ended Jun 30, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 60% and net income of $15M (7.7% of revenue). For the full year FY2025, revenue was $605M (+37% year on year) and net income $190M. Its largest product in Q2 2026 was Liver Product at $148M, 80% of the disclosed total, well ahead of Heart Product at 18%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 10, 2026Transition of Chief Financial Officer On September 10, 2026, the Board of Directors (the “Board”) of TransMedics Group, Inc. (the “Company”) appointed Fernando Araujo as Chief Financial Officer and Treasurer, effective as of September 21, 2026.Director or officer change · Form 8-K
- Aug 4, 2026TransMedics Reports Second Quarter 2026 Financial Results.Earnings release · press release
- May 5, 2026TransMedics Reports First Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $184.6MThe company’s own SEC segment disclosure.
- Liver Product$148.0M80%
- Heart Product$33.4M18%
- Lung Product$2.3M1%
- Service Unrelated To OCS Transplant$1.0M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.